CARA THERAPEUTICS INC (CARA)
US1407551092 - Common Stock
CARA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While CARA seems to be doing ok healthwise, there are quite some concerns on its profitability. CARA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CARA had negative earnings in the past year.
In the past year CARA has reported a negative cash flow from operations.
In the past 5 years CARA reported 4 times negative net income.
CARA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CARA has a Return On Assets of -94.19%. This is in the lower half of the industry: CARA underperforms 79.49% of its industry peers.
With a Return On Equity value of -207.65%, CARA is not doing good in the industry: 73.33% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.19% | ||
| ROE | -207.65% | ||
| ROIC | N/A |
ROA(3y)-58.96%
ROA(5y)-43.89%
ROE(3y)-100.1%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 70.44%, CARA is in the better half of the industry, outperforming 75.90% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for CARA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CARA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CARA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CARA has more shares outstanding
There is no outstanding debt for CARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CARA has an Altman-Z score of -9.44. This is a bad value and indicates that CARA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CARA (-9.44) is worse than 73.85% of its industry peers.
There is no outstanding debt for CARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.44 |
ROIC/WACCN/A
WACC9.29%
2.3 Liquidity
CARA has a Current Ratio of 4.54. This indicates that CARA is financially healthy and has no problem in meeting its short term obligations.
CARA has a Current ratio of 4.54. This is in the better half of the industry: CARA outperforms 62.56% of its industry peers.
CARA has a Quick Ratio of 4.43. This indicates that CARA is financially healthy and has no problem in meeting its short term obligations.
CARA has a Quick ratio of 4.43. This is in the better half of the industry: CARA outperforms 63.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.43 |
3. Growth
3.1 Past
The earnings per share for CARA have decreased strongly by -37.11% in the last year.
The Revenue for CARA has decreased by -49.87% in the past year. This is quite bad
Measured over the past years, CARA shows a quite strong growth in Revenue. The Revenue has been growing by 9.21% on average per year.
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-5.36%
Revenue 1Y (TTM)-49.87%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Revenue growth Q2Q-8.97%
3.2 Future
Based on estimates for the next years, CARA will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.51% on average per year.
CARA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 56.79% yearly.
EPS Next Y46.08%
EPS Next 2Y21.73%
EPS Next 3Y16.59%
EPS Next 5Y17.51%
Revenue Next Year-76.32%
Revenue Next 2Y-59.09%
Revenue Next 3Y-44.38%
Revenue Next 5Y56.79%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CARA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CARA's earnings are expected to grow with 16.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.73%
EPS Next 3Y16.59%
5. Dividend
5.1 Amount
No dividends for CARA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARA THERAPEUTICS INC
NASDAQ:CARA (4/26/2024, 1:06:48 PM)
0.7224
+0.02 (+3.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap39.49M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.19% | ||
| ROE | -207.65% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.54 | ||
| Quick Ratio | 4.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y46.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-49.87%
Revenue growth 3Y-46.26%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y